Cheryl Zigrand | Authors


Molecular Targets in Non-Small Cell Lung Cancer

November 15, 2013

Today, the treatment options for non-small cell lung cancer (NSCLC) in the United States include targeted therapies aimed at angiogenesis (bevacizumab), EGFR mutations (erlotinib and afatinib), and ALK translocations (crizotinib).

Multidisciplinary Perspectives: Molecular Testing in NSCLC

November 15, 2013

Testing for genetic abnormalities is important in NSCLC, both to ensure that as many patients as possible are benefit from approved therapies and to advance understanding of more targets that may be able to lead to future treatments.

World Conference on Lung Cancer 2013 Highlights

November 15, 2013

WCLC is the largest meeting dedicated to lung cancer and other thoracic malignancies. This year’s theme was “Next-Generation Lung Cancer Care,” and highlights from some key data presented are provided here.

Treating Squamous vs Nonsquamous Disease

November 15, 2013

The addition of bevacizumab, erlotinib, afatinib, and crizotinib to the treatment arsenal for NSCLC has been a major advance in the treatment of this disease. However, there is a large imbalance within tumor types.